Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted fromin-vivo rat data?
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
In a drug discovery environment, reasonable go/no-go human in-vivo pharmacokinetic (PK) decisions must be made in a timely manner with a minimum amount of animal in-vivo or in-vitro data. We have investigated the accuracy of the in-vivo correlation between rat and human for the prediction of the total systemic clearance (CL), the volume of distribution at steady state (Vss), and the half-life (t1/2) using simple allometric scaling techniques. We have shown, using a large diverse set of drugs, that a fixed exponent allometric scaling approach can be used to predict human in-vivo PK parameters CL, Vss and t(1/2) solely from rat in-vivo PK data with acceptable accuracy for making go/no-go decisions in drug discovery. Human in-vivo PK predictions can be obtained using the simple allometric scaling relationships CL(Human) approximately = 40 CL(Rat) (L/hr), Vss(Human) approximately = 200 Vss(Rat) (L), and t1/2(Human) approximately = 4 t1/2(Rat) (hr). The average fold error for human CL predictions for N = 176 drugs was 2.25 with 79% of the drugs having a fold error less than 3. The average fold error for human Vss predictions for N = 144 drugs was 1.85 with 84% of the drugs having a fold error less than 3. The average fold error for human t1/2 predictions for N = 145 drugs was 2.05 with 76% of the drugs having a fold error less than 3. Using these simple allometric relationships, the sorting of drug candidates into a low/medium/high/very high human classification scheme was also possible from rat data. Since these simple allometric relationships between rat and human CL, Vss, and t1/2 are reasonably accurate, easy to remember and simple to calculate, these equations should be useful for making early go/no-go in-vivo human PK decisions for drug discovery candidates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They reported that single-species scaling, particularly when anchored to physiologically based corrections, can yield acceptable predictions for many small molecules.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [62]
Citations
Cites
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232 · cited 1×
“The prediction of human in-vivo hepatic clearance (CLH) has been studied using several different humanized in-vitro systems such as, hepatic microsomes (14, 15), heterologously expressed cytochrome P450 (CYPs) enzymes (16) and hepatocytes (17 - 19).”
BackgroundThe Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987 · cited 7×
“Simple allometric methods using three animal species are thought not to be sufficiently accurate in predicting human drug half-lives to be of practical value (13,24,31).”
BackgroundMethodInfluentialThe prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 3×
“Both methods are related to the standard allometric equation (25):”
BackgroundMethodPrediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479 · cited 1×
“, well-stirred, parallel tube, or dispersion) for converting in-vitro intrinsic metabolic clearances (CLint) into in-vivo CLH values has been shown to be important for the predictive outcome of low and highclearance drugs (20).”
BackgroundPharmaceutical Statistics: Practical and Clinical Applications.
Wallenstein, S., & Bolton, S. (1986) · Journal of the American Statistical Association · doi:10.2307/2289267 · Cited by 430
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Pharmaceutical Statistics: Practical and Clinical Applications
Kershner, R. (1985) · Technometrics · doi:10.1080/00401706.1985.10488086 · Cited by 283
Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats
Chiou, W. L., & Barve, A. (1998) · Pharmaceutical Research · doi:10.1023/a:1011981317451 · Cited by 257 · cited 2×
“This lack of correlation between rat and human oral bioavailabilities is speculated to be more likely due to factors such as drug formulation and metabolism differences than absorption factors, since literature data indicates that the in-vivo oral absorption in rats is a good early predictor of human oral absorption (…”
BackgroundMethodDesign of drugs involving the concepts and theories of drug metabolism and pharmacokinetics
Smith, D. A., Jones, B., & Walker, D. K. (1996) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199605)16:3<267::aid-med3>3.0.co;2-x · Cited by 239
Research works printed but not linked: 2
- Spasov, A. A.; Stepanov, A.V.; Smirnova, L. A.; Petrov, V. I.; Shabasheva, I. G. (2002). Pharmacokinetics of rhythmidazol upon single intravenous administration. Eksperimental’naya i Klinicheskaya Farmakologiya 65(3), 57–61.
- Vo_eh, S.; Schmidlin, O.; Taeschner, W. (1989). Pharmacokinetic drug Data. In: Clinical Pharmacokinetic Drug Data Handbook 1989. ADIS Press Limited, New Zealand, p. 1–38.
Cited by
Animal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
Obach, R. S., Lombardo, F., & Waters, N. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020479 · Cited by 462
“Previous reports have focused on prediction methods that utilize animal pharmacokinetic data (Caldwell et al., 2004; Ward and Smith, 2004a,b; Jolivette and Ward, 2005; Evans et al., 2006; Mahmood et al., 2006; Martinez et al., 2006; Tang and Mayersohn, 2006; Fagerholm, 2007; McGinnity et al., 2007)…”
MethodAnimal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314
“the percentage < twofold error versus the correlation [50], and for the sensitivity, specificity, positive predictive value and negative predictive value [51].”
A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer
Whitley, M. J., Cardona, D. M., Lazarides, A. L., Spasojevic, I., Ferrer, J. M., Cahill, J., Lee, C.-L., Snuderl, M., Blazer, D. G., Hwang, E. S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0293 · Cited by 296
Hayes' Principles and Methods of Toxicology
(2014) · CRC Press eBooks · doi:10.1201/b17359 · Cited by 280
Pharmacology of bisphosphonates
Cremers, S., & Papapoulos, S. (2011) · Bone · doi:10.1016/j.bone.2011.01.014 · Cited by 217
“Both non-compartmental and compartmental pharmacokinetics are used during various phases of drug development and are important for establishing, for example, initial dose regimens in larger animals and humans from studies of smaller animals by so-called allometric scaling [52].”
MethodLombardo, F., Berellini, G., & Obach, R. S. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.082966 · Cited by 174
“…reports, of which we cite a few examples, have focused on scaling techniques (i.e., approaches and techniques that use animal pharmacokinetic data) (Caldwell et al., 2004; Ward and Smith, 2004a,b; Jolivette and Ward, 2005; Evans et al., 2006; Mahmood et al., 2006; Martinez et al., 2006; Tang and…”
BackgroundTotal Consumer Exposure to Polybrominated Diphenyl Ethers in North America and Europe
Trudel, D., Scheringer, M., von Goetz, N., & Hungerbühler, K. (2011) · Environmental Science & Technology · doi:10.1021/es1035046 · Cited by 171
Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors
Hill, A. B., Chen, M., Chen, C.-K., Pfeifer, B. A., & Jones, C. H. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.11.004 · Cited by 160
Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look
Ling, J., Zhou, H., Jiao, Q., & Davis, H. M. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337134 · Cited by 144
“Many approaches have been proposed in an effort to reduce prediction errors by incorporating different in vitro and in vivo correction factors into allometric equations.(1,24-26,30,31,55,56) Currently, the most widely accepted correction approach for small molecules is the “rule of exponents” developed by Mahmood and…”
BackgroundDavies, M., Jones, R. D. O., Grime, K., Jansson-Löfmark, R., Fretland, A. J., Winiwarter, S., Morgan, P., & McGinnity, D. F. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.004 · Cited by 123
Lombardo, F., Waters, N. J., Argikar, U. A., Dennehy, M. K., Zhan, J., Gunduz, M., Harriman, S. P., Berellini, G., Liric Rajlic, I., & Obach, R. S. (2013) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012440282 · Cited by 106
“There have been numerous publications where allometric scaling methods have been tested with data sets of various sizes.(5,6,8,24-27) However, in this analysis, we have attempted allometric scaling for every compound for which complete animal and human IV pharmacokinetic data sets were publicly available, so this shou…”
BackgroundMethodDi, L., Feng, B., Goosen, T. C., Lai, Y., Steyn, S. J., Varma, M. V. S., & Obach, R. S. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054031 · Cited by 107
“(Caldwell et al., 2004).”
Pharmacokinetic Allometric Scaling of Antibodies: Application to the First-In-Human Dose Estimation
Mahmood, I. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21682 · Cited by 95
Berellini, G., Springer, C., Waters, N. J., & Lombardo, F. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9004658 · Cited by 92
Chen, Y., Smith, M. L., Sheets, M. P., Ballaron, S. J., Trevillyan, J. M., Burke, S. E., Rosenberg, T. A., Henry, C. L., Wagner, R., Bauch, J. L., et al. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3180325b0a · Cited by 83
Lombardo, F., Waters, N. J., Argikar, U. A., Dennehy, M. K., Zhan, J., Gunduz, M., Harriman, S. P., Berellini, G., Rajlic, I. L., & Obach, R. S. (2013) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012440281 · Cited by 86
Gombar, V. K., & Hall, S. D. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400001u · Cited by 94
Strategy for Extending Half-life in Drug Design and Its Significance
Günaydin, H., Altman, M. D., Ellis, J. M., Fuller, P. H., Johnson, S. A., Lahue, B. R., & Lapointe, B. T. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00018 · Cited by 82
Grime, K. H., Barton, P., & McGinnity, D. F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300476z · Cited by 78
Fagerholm, U. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.6.0007 · Cited by 76
Maass, C., Stokes, C. L., Griffith, L. G., & Cirit, M. (2017) · Integrative Biology · doi:10.1039/c6ib00243a · Cited by 72
Brightman, F. A., Leahy, D. E., Searle, G. E., & Thomas, S. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004804 · Cited by 69
Rowley, H. L., Kulkarni, R. S., Gosden, J., Brammer, R. J., Hackett, D., & Heal, D. J. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113513850 · Cited by 65
“When a 10-fold factor is applied to take into account the allometric and pharmacokinetic differences between humans and rats (Caldwell et al., 2004), these doses would translate to oral doses in rats of 10–13 mg/kg for lisdexamfetamine dimesylate, 3.”
MethodIn silico Prediction of Total Human Plasma Clearance
Berellini, G., Waters, N. J., & Lombardo, F. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300155y · Cited by 65
Clearance Mechanism Assignment and Total Clearance Prediction in Human Based upon in Silico Models
Lombardo, F., Obach, R. S., Varma, M. V., Stringer, R., & Berellini, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500436v · Cited by 60
IntegratinginvitroADMET data through generic physiologically based pharmacokinetic models
Leahy, D. E. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.4.619 · Cited by 66
de Oliveira, A. G., & Gomes‐Marcondes, M. C. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2424-9 · Cited by 61
“Metformin concentration was estimated using the allometric scaling [18, 19] from human data, using the initial recommended dose for T2DM patients (500 mg/day).”
MethodDivide and conquer? Size adjustment with allometry and intermediate outcomes
Nakagawa, S., Kar, F., O’Dea, R. E., Pick, J. L., & Lagisz, M. (2017) · BMC Biology · doi:10.1186/s12915-017-0448-5 · Cited by 53
Brightman, F. A., Leahy, D. E., Searle, G. E., & Thomas, S. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004838 · Cited by 60
Jansen, K., Casellas, C. P., Groenink, L., Wever, K. E., & Masereeuw, R. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.018 · Cited by 55
Fagerholm, U. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.9.0001 · Cited by 53
Cai, H., Nguyen, N. T., Peterkin, V. C., Yang, Y.-S., Hotz, K. J., Beaton, D., Chen, S., Tukey, R. H., & Stevens, J. C. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.030130 · Cited by 47
“Additionally, allometric scaling based on in vivo preclinical models has been successful for P450-eliminated drugs, provided that species specific P450 enzymes have been well studied and understood (Caldwell et al., 2004; De Buck et al., 2007).”
MethodBagal, S. K., Bungay, P. J., Denton, S. M., Gibson, K. R., Glossop, M. S., Hay, T. L., Kemp, M. I., Lane, C. A. L., Lewis, M. L., Maw, G. N., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00059 · Cited by 45
Tess, D. A., Chang, G., Keefer, C. E., Carlo, A. A., Jones, R., & Di, L. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00800-x · Cited by 49
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models
Siramshetty, V. B., Shah, P., Kerns, E. H., Nguyen, K., Yu, K. R., Kabir, M., Williams, J., Neyra, J., Southall, N. T., Nguyễn, Ð.-T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77327-0 · Cited by 52
Haraya, K., Tachibana, T., & Nezu, J. (2017) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.05.002 · Cited by 43
Defining the Role of Pharmacology in the Emerging World of Translational Research
Enna, S. J., & Williams, M. J. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57001-3 · Cited by 51
Smith, P. W., Zuccotto, F., Bates, R. H., Martínez, M. S., Read, K. D., Peet, C. F., & Epemolu, O. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00160 · Cited by 49
Prediction of volume of distribution at steady state in humans: comparison of different approaches
Zou, P., Zheng, N., Yang, Y., Yu, L. X., & Sun, D. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.682569 · Cited by 46
“Conventionally, Vdss is extrapolated to human by allometric scaling with body weight across species (Table 1) [18,19].”
BackgroundMethodWang, J. L., Aston, K. W., Limburg, D. C., Ludwig, C., Hallinan, A. E., Koszyk, F. J., Hamper, B. C., Brown, D. L., Graneto, M. J., Talley, J. J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.059 · Cited by 37
Huang, C., Zheng, M., Yang, Z., Rodrigues, A. D., & Marathe, P. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9411-4 · Cited by 36
Evans, C. A., Jolivette, L. J., Nagilla, R., & Ward, K. W. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006619 · Cited by 32
Maia‐de‐Oliveira, J. P., Soares, B. L., Ramalho, T. E. B., Gavioli, E. C., Soares-Rachetti, V. D. P., Teixeira, L., Baker, G. B., Dursun, S. M., & Hallak, J. E. C. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.035 · Cited by 37
“With regard to translation to the clinic, these findings with rats, which have an even faster metabolic rate than humans (Caldwell et al., 2004), suggest that SNP on its own could be responsible for the therapeutic effects up to 4 weeks found in our previous clinical study (Hallak et al.”
BackgroundPlasma Protein Binding as an Optimizable Parameter for Acidic Drugs
Gardiner, P., Cox, R. J., & Grime, K. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.087163 · Cited by 32
“It has been noted previously that while standard allometric scaling approaches offer fairly poor predictivity of human CL (Caldwell et al., 2004; Ward and Smith, 2004), the work of Ward and Smith highlights that human effective half-life often approximates to 4 times rat half-life, offering a…”
BackgroundThe Impact of Hepatic Uptake on the Pharmacokinetics of Organic Anions
Gardiner, P., & Paine, S. W. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039842 · Cited by 34
Cornec, A., James, M. J., Kovalevich, J., Trojanowski, J. Q., Lee, V. M. ‐., Smith, A. B., Ballatore, C., & Brunden, K. R. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.03.002 · Cited by 30
Mahmood, I. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21597 · Cited by 31
“However, to date one or two-species allometric scaling for the prediction of human drug clearance has been found to be relatively inaccurate.(3,4,12,19) In a recent article, Tang et al.”
BackgroundJeong, Y., Yim, C.-S., Ryu, H.-M., Noh, C., Song, Y.-K., & Chung, S. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.01.026 · Cited by 29
Physicologically Based Toxicokinetic Models of Tebuconazole and Application in Human Risk Assessment
Jónsdóttir, S. Ó., Reffstrup, T. K., Petersen, A., & Nielsen, E. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00341 · Cited by 30
Predicting Total Clearance in Humans from Chemical Structure
Yu, M. J. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci1000295 · Cited by 28
Binder, U., & Skerra, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010124 · Cited by 27
“the range of several days can be expected for Tα1-PAS in humans [56,57], which would allow weekly dosing while achieving a lasting pharmacological effect.”
BackgroundAllometric Scaling in Pharmacokinetic Studies in Anesthesiology
Eleveld, D. J., Koomen, J. V., Absalom, A. R., Su, H., Hannivoort, L. N., & Struys, M. M. R. F. (2022) · Anesthesiology · doi:10.1097/aln.0000000000004115 · Cited by 25
Sobiech, M., Giebułtowicz, J., & Luliński, P. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c05985 · Cited by 23
Sun, C., Trevaskis, J. L., Jodka, C. M., Neravetla, S., Griffin, P., Xu, K., Wang, Y., Parkes, D. G., Forood, B., & Ghosh, S. S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401418s · Cited by 22
Marklund, M., Strömberg, E. A., Lærke, H. N., Knudsen, K. E. B., Kamal‐Eldin, A., Hooker, A. C., & Landberg, R. (2014) · Journal of Nutrition · doi:10.3945/jn.114.196220 · Cited by 25
“Distribution volumes of the alkylresorcinol metabolites DHBA and DHPPA were estimated by allometric scaling (28) of estimates determined in a previously published study using rats (9).”
MethodToward an integrated human clearance prediction strategy that minimizes animal use
Beaumont, K. C., Gardner, I. B., Chapman, K. L., Hall, M., & Rowland, M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22635 · Cited by 23
Bae, J., Kwon, M., Lee, Y., Lee, E., Choi, B., & Noh, G. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.06.066 · Cited by 21
Espiritu, M. J., Chen, J., Yadav, J., Larkin, M., Pelletier, R. D., Chan, J. M., GC, J. B., Natesan, S., & Harrelson, J. P. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000087 · Cited by 23
Veryser, L., Taevernier, L., Joshi, T. A., Tatke, P. A., Wynendaele, E., Bracke, N., Stalmans, S., Peremans, K. Y., Burvenich, C., Risseeuw, M., et al. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1159-0 · Cited by 22
Thomas, S. (2009) · Alternatives to Laboratory Animals · doi:10.1177/026119290903700507 · Cited by 21
“clearance data measured in the rat (23, 25).”
MethodCraving espresso: the dialetics in classifying caffeine as an abuse drug
dos Santos, M. K. F., Gavioli, E. C., Rosa, L. S., Soares-Rachetti, V. D. P., & Soares, B. L. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1570-9 · Cited by 19
Petersson, C., Papasouliotis, O., Lecomte, M., Badolo, L., & Dolgos, H. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1625084 · Cited by 19
“The most commonly used methods include various forms of allometric scaling, single-species scaling, species proportionality and physiologically based pharmacokinetic (PBPK) modeling (Bjorkman 2002; Boxenbaum 1982; Caldwell et al., 2004; Poulin & Theil 2002).”
MethodTan, M. L., Basu, D., Kwiecień, J. M., Johnson, R. L., & Mishra, R. K. (2013) · Peptides · doi:10.1016/j.peptides.2013.02.004 · Cited by 17
Poth, A. G., Huang, Y., Le, T. T., Kan, M., & Craik, D. J. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.001 · Cited by 16
Obach, R. S. (2007) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(07)42030-9 · Cited by 18
Tang, H., Hussain, A., Leal, M., Fluhler, E., & Mayersohn, M. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22316 · Cited by 13
Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans
Teitelbaum, Z., Lavé, T., Freijer, J. I., & Cohen, A. F. (2010) · Clinical Pharmacokinetics · doi:10.2165/11533760-000000000-00000 · Cited by 15
Karara, A. H., Edeki, T. I., McLeod, J. F., Tonelli, A. P., & Wagner, J. A. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009344987 · Cited by 14
PKSmart: An Open-Source Computational Model to Predict in vivo Pharmacokinetics of Small MoleculesPreprint
Seal, S., Trapotsi, M., Subramanian, V., Spjuth, O., Greene, N., & Bender, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.02.578658 · Cited by 14
Caldwell, G. W., Ritchie, D. M., Masucci, J. A., Hageman, W., Cotto, C., Hall, J., Hasting, B., & Jones, W. J. (2005) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03226411 · Cited by 14
Moussa, B. A., El‐Zaher, A. A., El-Ashrey, M. K., & Fouad, M. A. (2018) · Drug Testing and Analysis · doi:10.1002/dta.2562 · Cited by 13
Allometric basis of enrofloxacin scaling in green iguanas
Maxwell, L. K., & Jacobson, E. R. (2007) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2007.00915.x · Cited by 13
Drug Metabolism: Significance and Challenges
Prakash, C., & Vaz, A. D. N. (2008) · Wiley eBooks · doi:10.1002/9780470409107.ch1 · Cited by 13
Pharmacokinetic allometric scaling of coagulation factors and tissue‐type plasminogen activators
Mahmood, I. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02054.x · Cited by 12
Zhang, M., Van, L. M., & Amiji, M. M. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102686 · Cited by 13
Williams, M. J., Mullane, K., & Curtis, M. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804725-5.00005-7 · Cited by 13
Poth, A. G., Chiu, F. C. K., Stalmans, S., Hamilton, B. R., Huang, Y., Shackleford, D. M., Patil, R., Le, T. T., Kan, M., Durek, T., et al. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100087 · Cited by 13
Novel antimicrobial lipopeptides with long in vivo half-lives
Pasetka, C., Erfle, D. J., Cameron, D. R., Clement, J. J., & Rubinchik, E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.013 · Cited by 11
Brown, D. G. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02863 · Cited by 12
Hu, Y., & Smith, D. E. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084236 · Cited by 13
“They included values based on: 1) in silico human Peff of 0.35 1024 cm/s (ADMET Predictor); 2) rat Peff of 0.75 1024 cm/s (Caldwell et al., 2004); 3) WT mouse Peff; and 4) huPepT1 mouse Peff (Hu and Smith, 2016).”
MethodInfluentialPreclinical Pharmacokinetics and Safety of Intravenous RTD-1
Park, A. Y. J., Tran, D. Q., Schaal, J. B., Wang, M., Selsted, M. E., & Beringer, P. M. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02125-21 · Cited by 9
“, CL or Vss), BW is the body weight of the species, a is an allometric coefficient, and b is an allometric exponent (33, 37).”
BackgroundAndo, H., Izawa, S., Hori, W., & Nakagawa, I. (2008) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-5-19 · Cited by 12
Reichard, E. E., Nanaware‐Kharade, N., Gonzalez, G. A., Thakkar, S., Owens, S. M., & Peterson, E. C. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2017-y · Cited by 11
“Based on allometric scaling (48), the predicted half-life in”
BackgroundPharmacokinetic Allometric Scaling of Oligonucleotides
Mahmood, I. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0299 · Cited by 10
“In general, 1 or 2 species scaling has not been found successful (Boxenbaum, 1982; Caldwell et al., 2004; Goteti et al., 2010).”
Toxicologic Assessment of Pharmaceutical and Biotechnology Products
Dorato, M. A., McMillian, C. L., & Williams, T. (2014) · CRC Press eBooks · doi:10.1201/b17359-10 · Cited by 10
Lovelock, D. F., Nguyen, T., Voorhies, K. J. V., Zhang, Y., & Besheer, J. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000919 · Cited by 9
ADME Optimization in Drug Discovery
McGinnity, D. F., & Grime, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12365-0 · Cited by 10
Yoshida, T. (2010) · Journal of Applied Toxicology · doi:10.1002/jat.1522 · Cited by 10
Lombardo, F., Obach, R. S., & Waters, N. J. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch9 · Cited by 9
Ngo, L. T., Yun, H., & Chae, J. (2023) · Pharmaceuticals · doi:10.3390/ph16050684 · Cited by 8
Najri, B. A., Saidi, K. M., Guendouzi, A., Khelili, S., & Kıvrak, A. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500895 · Cited by 8
Singh, R., Moreno, M., & Stanimirovic, D. B. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00691-3 · Cited by 10
Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents
Han, M., Pan, M., Xiao, G., Yuan, Y., Chen, S., & Zou, Z. Z. (2023) · Molecules · doi:10.3390/molecules28124628 · Cited by 7
“Here in this paper, the ADME (absorption, distribution, metabolism, and excretion) and PK (pharmacokinetics) profile were first measured, such as the PPB (plasma protein binding), metabolic stability, half-life, volume of distribution [14], and so on.”
MethodInfluential[No influence of urinary nitrate excretion on the goitre prevalence in Germany].
Hampel, R., Zöllner, H., Glass, A., & Schönebeck, R. (2003) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-003-1303-8 · Cited by 8
Seal, S., Trapotsi, M., Mahale, M., Subramanian, V., Greene, N., Spjuth, O., & Bender, A. (2025) · Journal of Cheminformatics · doi:10.1186/s13321-025-01066-5 · Cited by 22
“Other methods of estimating pharmacokinetics (PK) parameters include allometric scaling [4] (or single-species scaling) and physiologically based pharmacokinetic modelling (PBPK) [5].”
ADME Optimization in Drug Discovery
McGinnity, D. F., & Grime, K. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00298 · Cited by 9
Preclinical Pharmacology and Toxicology - Contributions to the Translational Interface ☆
McGonigle, P., & Williams, M. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.05242-9 · Cited by 6
Reproducibility in Biomedical Research
Mullane, K., Curtis, M. J., & Williams, M. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804725-5.00001-x · Cited by 11
Shah, P., Padilha, E. C., Kato, R., Siramshetty, V. B., Huang, W., & Xu, X. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.08.002 · Cited by 5
“Additionally, this data plays a crucial role in establishing in vitro-in vivo correlations, which instills confidence in extrapolating in vivo clearance for other species, including humans [3,4].”
Background
Metadata
- Authors
- Caldwell, G. W., Masucci, J. A., Yan, Z., & Hageman, W.
- Affiliations
- Janssen Research & Development (United States) (US)
- ORCID
- Yan, Zhengyin
- Venue
- European Journal of Drug Metabolism and Pharmacokinetics
- Published
- 2004-06
- Volume
- 29
- Issue
- 2
- Pages
- 133-143
- ISSN
- 0378-7966 (ISSN-L)
- 2107-0180
- OpenAlex
- W2019418677
- Cited by
- 148
- References
- 56
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 4 · 2023: 7 · 2022: 2 · 2021: 6 · 2020: 9 · 2019: 4 · 2018: 7 · 2017: 10 · 2016: 8 · 2015: 5 · 2014: 8 · 2013: 7 · 2012: 8
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Drug Metabolism and Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- allometric scaling, pharmacokinetic prediction, rat-to-human extrapolation, half-life, go/no-go decisions, drug discovery
- MeSH terms
- Algorithms, Animals, Half-Life, Humans, Pharmacokinetics, Predictive Value of Tests, Regression Analysis, Species Specificity, Drug Design, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.